Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22 Mar '23 Mar '24 Mar '25 Mar '26
Cash and Short Term Investments
139.56 180.17 169.35 137.31 192.31 259.50 284.47 178.80 306.76 245.44
Receivables
152.68 151.23 185.03 165.21 127.56 159.38 179.14 206.56 202.66 216.86
Inventory
176.93 160.80 194.34 270.28 322.61 293.03 259.38 317.20 365.14 306.37
Total current assets
510.03 521.18 576.12 603.64 693.55 756.03 769.72 768.90 934.98 834.88
Property, Plant, Equpment (Net)
323.86 332.16 343.98 253.40 217.56 258.48 310.89 311.36 284.05 305.76
Goodwill and Intangible Assets (Total)
388.38 367.98 338.51 343.76 831.93 777.55 742.00 971.20 1,060.01 1,104.02
Long Term Assets (Tax, Deferred)
3.99 3.96 4.36 3.93 6.01 4.47 5.24 7.74 7.80 9.52
Long-term assets (Other)
12.45 12.06 11.80 62.38 70.88 63.21 106.98 136.39 164.11 141.74
Total non-current assets
728.68 716.16 698.65 663.47 1,126.38 1,103.70 1,165.10 1,426.69 1,515.97 1,561.05
Total Assets
1,238.71 1,237.34 1,274.77 1,267.11 1,819.92 1,859.73 1,934.83 2,195.59 2,450.95 2,395.93
Notes Payable
61.02 194.26 27.67 76.98 17.02 214.15 11.78 10.23 303.56 5.02
Accounts Payable
42.97 55.27 63.36 50.73 50.29 58.37 63.93 73.36 67.00 51.06
Accrued Expenses
43.53 69.52 53.20 49.47 47.60 48.54 64.48 80.71 59.42 68.19
Other current liabilities
63.65 65.66 91.53 97.64 138.59 121.21 111.63 136.09 148.13 158.34
Total current liabilities
211.18 384.70 235.76 274.82 253.50 442.27 251.82 300.38 578.11 282.60
Long Term Debt (Total)
253.63 59.42 322.45 305.51 690.59 559.44 754.10 797.56 921.23 1,219.57
Long Term Tax Liability (Deferred)
12.11 6.53 19.91 10.56 43.83 28.73 36.20 62.64 62.58 38.05
Non-current Liabilities (Other)
22.18 34.26 28.78 89.10 100.34 79.88 74.72 75.04 68.19 59.39
Total non-current liabilities
287.92 100.21 371.14 405.18 834.76 668.04 865.01 935.25 1,052.00 1,317.01
Total liabilities
499.10 484.91 606.90 680.00 1,088.25 1,110.31 1,116.83 1,235.63 1,630.11 1,599.61
Additional Paid In Capital
482.04 503.96 536.32 553.23 602.73 572.48 594.71 634.63 523.26 554.14
Common Stock (Net)
0.52 0.52 0.51 0.50 0.51 0.51 0.50 0.51 0.48 0.45
Retained Earnings
289.92 266.94 161.42 78.51 157.98 202.39 253.17 360.46 352.17 279.34
Common Equity (Total)
739.61 752.43 667.87 587.11 731.67 749.42 818.00 959.96 820.84 796.32
Shareholders Equity (Total)
739.61 752.43 667.87 587.11 731.67 749.42 818.00 959.96 820.84 796.32
Shareholders Equity and Liabilities (Total)
1,238.71 1,237.34 1,274.77 1,267.11 1,819.92 1,859.73 1,934.83 2,195.59 2,450.95 2,395.93
Shares (Common)
52.26 52.34 51.02 50.32 50.87 51.12 50.45 50.79 48.22 45.25
Shareholders Equity (Tangible)
351.23 384.44 329.36 243.35 (100.26) (28.12) 76.00 (11.24) (239.18) (307.70)
Net Debt
114.06 (120.75) 153.10 168.20 498.29 299.95 469.64 618.76 614.47 974.13
Total Debt
253.63 59.42 322.45 305.51 690.59 559.44 754.10 797.56 921.23 1,219.57

Fold the line items

In millions of $ except per-share values · columns are period end dates